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Abstract
Background: Insulin-like growth factor binding protein (IGFBP-3) is an antiproliferative, pro-
apoptotic and invasion suppressor protein which is transcriptionally regulated by p53. Promoter
methylation has been linked to gene silencing and cancer progression. We studied the correlation
between IGFBP-3 and p53 expression as well as IGFBP-3  promoter methylation in ovarian
endometrioid carcinoma (OEC) by immunohistochemical staining and quantitative methylation-
specific PCR (qMSP). Additionally, we assessed the molecular regulatory mechanism of wild type
(wt) p53 on IGFBP-3 expression using two subclones of OEC, the OVTW59-P0 (low invasive) and
P4 (high invasive) sublines.
Results: In 60 cases of OEC, 40.0% showed lower IGFBP-3 expression which was significantly
correlated with higher IGFBP-3 promoter methylation. p53 overexpression was detected in 35.0%
of OEC and was unrelated to clinical outcomes and IGFBP-3. By Kaplan-Meier analysis, patients
with lower IGFBP-3, higher IGFBP-3 promoter methylation, and normal p53 were associated most
significantly with lower survival rates. In OEC cell line, IGFBP-3 expression was correlated with
IGFBP-3 promoter methylation. IGFBP-3 expression was restored after treatment with a DNA
methy-transferase inhibitors (5-aza-deoxycytidine) and suppressed by a p53 inhibitor (pifithrin-α).
The putative p53 regulatory sites on the promoter of IGFBP-3 were identified at -210, -206, -183
and -179 bases upstream of the transcription start site. Directed mutagenesis at these sites
quantitatively reduced the transcription activity of IGFBP-3.
Conclusion: Our data suggests that IGFBP-3 silencing through IGFBP-3 promoter methylation in
the absence of p53 overexpression is associated with cancer progression. These results support a
potential role of IGFBP-3 methylation in the carcinogenesis of OEC.
Background
Epithelial ovarian cancer is the most lethal gynecological
cancer among women worldwide. Metastasis occurs in
most patients before diagnosis, and the majority of
patients have high subsequent recurrent rate after com-
pleting surgery and chemotherapy [1]. Survival is at about
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3 years for patients in advanced stages [2]. The poor prog-
nosis of ovarian cancer is due to the difficulty in early
diagnosis and the detrimental processes of invasion and
metastasis. A better understanding of the molecular mech-
anisms of cancer development and progression will help
to improve the diagnosis and treatment of the disease.
Insulin-like growth factor binding proteins (IGFBPs) are
circulating transport proteins for IGF, with IGFBP-3 being
the predominant IGFBP in circulation [3]. IGFBP-3 can
regulate cell growth and death, either dependent or inde-
pendent of its interaction with IGF [3,4]. Recently, we
have further identified IGFBP-3 as an invasion suppressor
gene using an established ovarian cancer cell line
OVTW59-P0 and its sublines P1 to P4, which were
obtained from a gradual invasion model with sequential
increase in invasiveness [5]. Many tumor suppressor genes
involved in cancer formation and progression are fre-
quently epigenetically silenced through aberrant hyper-
methylation at their promoter regions [6]. In ovarian
cancer, genes with promoter hypermethylation are fre-
quently found to be related to cancer progression [7,8].
Aberrant promoter hypermethylation of IGFBP-3  and
gene silencing are observed in many cancers, such as lung,
hepatocellular, gastric, colorectal, breast, and ovarian can-
cers [9-13]. However, the association of IGFBP-3  pro-
moter hypermethylation with poor clinical outcome was
identified only at early stages in lung and ovarian cancers
[9,10].
p53 is a known transcription factor for IGFBP-3 expres-
sion [9]. Induction of IGFBP-3 by p53 has been shown to
cause cell apoptosis in an IGF-independent manner [14].
Eleven p53 binding sites have been identified within
IGFBP-3 gene based on the homology to the p53 binding
consensus sequence, and confirmation by electrophoretic
mobility shift analyses [15]. Promoter hypermethylation
at these p53 binding sites caused gene silencing and resist-
ance to p53 [16]. Therefore, it has been suggested that p53
could mediate cross-talk to the IGF axis through IGFBP-3
regulation [14].
Pathologically, epithelial ovarian cancer is classified into
four major histological subtypes: serous, mucinous,
endometrioid and clear cell carcinoma. Each subtype is
associated with distinct molecular alterations [17]. In our
previous study, we found 51.4% of the ovarian endome-
trioid carcinoma (OEC) subtype showing lower IGFBP-3
expression, which is associated significantly with poor
patient outcome [5]. From literature review, p53 overex-
pression is more frequently reported in the serous subtype
of ovarian cancer [18-20]. The association of altered p53
expression in tumor tissue with patient survival in ovarian
cancer is still under debate [19-21], but a significant cor-
relation is often reported in the serous subtype [18,19].
Despite the close molecular regulation between p53 and
IGFBP-3 being known for more than a decade [9], little
information concerning p53 regulation of IGFBP-3 or the
effect of epigenetic inactivation of IGFBP-3 exist with
defined clinical endpoints. In the current study, we ana-
lyzed the association between p53 and IGFBP-3 expres-
sion in ovarian cancer progression. We explored the
clinical significance of aberrant promoter hypermethyla-
tion at the p53 binding sites of IGFBP-3 in OEC. Func-
tional analysis of p53 regulation on IGFBP-3 expression
was further assessed using the OVTW59-P0 and P4 cell
lines. Our study indicates that methylation at the p53
transcription factor binding sites in the IGFBP-3 promoter
can silence IGFBP-3 expression and hence lead to cancer
progression in OEC.
Results
IGFBP-3 expression was correlated with IGFBP-3 promoter 
methylation, but not p53 expression
A total of 60 OEC patients with an average age at surgery
of 51.5 ± 12.4 years old were recruited. Among these
patients, 41.7% were in the advanced disease stages
(stages 3 and 4) and 61.8% at higher histological grades
(grades 2 and 3) (Table 1). By immunohistochemical
staining, IGFBP-3 was located in the tumor cytoplasm and
p53 was immunoreactive at the nucleus (Figure 1).
The amount of methylation at IGFBP-3 promoter in these
patient samples was measured by quantitative real time
methylation specific PCR (qMSP). Twenty samples were
unable to be bisulfite converted probably due to failed in
DNA extraction from very old paraffin blocks. In total,
Immunohistochemical staining Figure 1
Immunohistochemical staining. High IGFBP-3 expres-
sion and normal p53 in a case of grade 1 OEC (a and b); and 
low IGFBP-3 expression and overexpression of p53 in a case 
of grade 3 OEC (c and d) (a - d, H&E, × 200).Molecular Cancer 2009, 8:120 http://www.molecular-cancer.com/content/8/1/120
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qMSP analysis was performed on 40 patient samples.
There were no differences in IGFBP-3 and p53 expressions
or in clinicopathological features between the samples
which were unable to be analyzed by qMSP and those
which were (Additional file 1, Table S1). Among these 40
samples, the calculated promoter methylation of IGFBP-3
ranged from 0.01 to 59.8%. By using receiver operating
characteristic (ROC) curve and area under the curve
(AUC) analysis methods, the optimal cutoff value was set
at a threshold of > 3% as hypermethylation. At this thresh-
old, the sensitivity of IGFBP-3  methylation with low
IGFBP-3 expression was 0.86 and the specificity was 0.73
(Additional file 1, Figure S1).
Table 1 shows the correlation among IGFBP-3 and p53
expression and qMSP results with the clinical parameters.
High IGFBP-3 expression was found in tumors of lower
grades and lower stages, and p53 tended to be overex-
pressed in tumors with higher grades. No correlation was
found between p53 overexpression and IGFBP-3 expres-
sion or IGFBP-3  promoter methylation. Cases that
showed higher IGFBP-3 methylation (at threshold > 3%)
were significantly correlated with lower IGFBP-3 expres-
sion and higher histological grades.
The calculated IGFBP-3 methylation from qMSP analysis
was further subdivided into four quartiles, and Table 2
shows the relation between IGFBP-3 expression and clin-
icopathological features for each quartile. Again, we
observed a close association of high IGFBP-3 expression
with ≤ 3% methylation and low IGFBP-3 expression with
> 3% methylation. However, 2 cases showed low IGFBP-3
expression and ≤ 3% methylation and 8 cases showed
high IGFBP-3 expression and > 3% methylation. These
associations were opposite to the parallel relationship of
methylation and IGFBP-3 suppression and were thus
grouped into the unparallel category (Table 3).
Clinical correlation of IGFBP-3 expression, p53 
overexpression and IGFBP-3 promoter methylation with 
survival rates
Cox-regression analysis revealed low IGFBP-3 expression
to be associated with lower progression-free survival (PFS)
and lower overall survival (OS) rates. p53 overexpression
Table 1: Tumor expressions of IGFBP-3, p53 and IGFBP-3 promoter methylation and the clinicopathological features in patients with 
OEC.
Characteristics IGFBP-3 p53 IGFBP-3 Methylation
High
N = 36
Low
N = 24
p value Normal 
N = 39
Overexpression 
N = 21
p-value ≤ 3% 
N = 20
> 3%
N = 20
p value
Age (mean ± SD) 51.7 ± 11.9 52.2 ± 12.7 0.88 49.3 ± 12.3 55.7 ± 11.7 0.06 51.8 ± 12.9 51.5 ± 13.3 0.94
Stage
I2 2 6 2 0 8 1 1 8
II 5 2 0.02 5 2 0.54 4 1 0.24
III 9 15 14 10 5 10
I V 01 01 01
Grade
11 9 0 1 6 3 1 1 4
2 11 12 < 0.001 12 11 0.09 5 9 0.05
36 1 1 1 1 6 3 7
Low IGFBP-3 17 (43.6%) 7 (33.3%) 0.77 2 (10.0%) 12 (60.0%) 0.003
p53 overexpression 14 (38.9%) 7 (29.2%) 0.62 8
(12.5%)
6 (30.0%) 0.11
Table 2: Relation among the four quartiles of IGFBP-3 promoter methylation by qMSP analysis with IGFBP-3 expression and 
clinicopathological features in OEC patients.
Quartiles IGFBP-3 methylation
(% range)
Number of patients (%)
Low IGFBP-3 Advanced stage Higher grade Patients with
recurrent tumor
Patients expired
First 0.01 -- 1.07 1 (10) 4 (40) 4 (40) 4 (40) 2 (20)
Second 1.12 -- 2.83 1 (10) 1 (10) 5 (50) 2 (20) 2 (20)
Third 3.10 -- 6.36 5 (50) 5 (50) 9 (90) 5 (50) 5 (50)
fourth 6.88 -- 59.79 7 (70) 6 (60) 7 (70) 5 (50) 4 (40)
Advanced stage was defined as stage 3 or 4.
Higher histological grade was defined as grade 2 or 3.M
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Table 3: Survival Analysis for patients with OEC.
Variables Case 
number
PFS OS
Unadjusted Adjusted* Unadjusted Adjusted*
HR 95% CI p value HR 95% CI p value HR 95% CI p value HR 95% CI p value
IGFBP-3
High 36 1.00 1.36-7.77 0.01 1.00 0.27-2.27 0.65 1.00 1.28-9.38 0.01 1.00 0.27-2.85 0.82
Low 24 3.25 0.78 3.46 0.87
P53
Normal 39 1.00 0.43-2.42 0.97 1.00 0.53-3.74 0.49 1.00 0.29-2.02 0.60 1.00 0.24-2.32 0.62
Overexpression 21 1.01 1.41 0.77 0.75
Methylation
≤ 3% 20 1.00 0.76-5.82 0.14 1.00 0.20-2.033 0.45 1.00 0.91-9.60 0.07 1.00 0.16-2.45 0.49
> 3% 20 2.11 0.64 2.95 0.62
IGFBP-3 expression and IGFBP-3 methylation
High IGFBP-3
Methylation ≤ 3%
18 1.00 1.00 1.00 1.00
Unparallel 10 2.38 0.53-10.64 0.26 1.46 0.09-2.49 0.37 3.16 0.53-19.01 0.21 0.56 0.08-3.78 0.56
Low IGFBP-3
Methylation > 3%
12 4.45 1.17-16.85 0.03 0.37 0.07-1.88 0.23 7.18 1.48-34.89 0.02 0.64 0.11-3.68 0.62
IGFBP-3 expression and IGFBP-3 methylation with normal p53
High IGFBP-3
Methylation ≤ 3%
10 1.00 1.00 1.00 1.00
Unparallel 6 4.67 0.58-37.40 0.15 0.47 0.03-7.09 0.56 4.81 0.57-40.40 0.15 0.37 0.18-7.68 0.52
Low IGFBP-3
Methylation > 3%
8 21.47 2.57-179.19 0.005 0.40 0.07-28.05 0.82 20.38 2.39-173.89 0.006 0.79 0.27-23.40 0.89
PFS indicates progression-free survival; OS indicates overall survival; HR indicates hazard ratio; 95% CI confidence interval; IGFBP-3, insulin-like growth factor binding protein-3; Unparallel 
indicates either high IGFBP-3 and IGFBP-3 promoter methylation > 3% or low IGFBP-3 and IGFBP-3 promoter methylation ≤ 3%.
*Adjusted by age at diagnosis, disease stage and histological grade.Molecular Cancer 2009, 8:120 http://www.molecular-cancer.com/content/8/1/120
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was not associated with patient survivals while high
IGFBP-3 promoter methylation was marginally associated
with lower OS. When combining these variables for sur-
vival analysis, low IGFBP-3 expression, high IGFBP-3 pro-
moter methylation and normal p53 expression were
correlated most significantly with lower PFS and OS.
However, since IGFBP-3 expression and IGFBP-3  pro-
moter methylation were correlated with disease stages and
tumor grades (Table 1), the associations of these variables
with survival rates was not independent of age, stage and
grade (Table 3).
Figure 2 shows Kaplan Meier survival estimates of patients
classified by IGFBP-3 expression, methylation levels of
IGFBP-3 promoter and p53 expression. For comparison,
Additional file 1, Figure S2 shows the survival estimates
classified by IGFBP-3 expression and IGFBP-3 promoter
methylation levels in all patients with tumors that showed
either normal or overexpressed p53. The association of
patient PFS and OS with IGFBP-3 expression and IGFBP-3
promoter methylation were less significant comparing to
the results when only cases with normal p53 were
included (Figure 2d).
Correlation of IGFBP-3 promoter methylation and IGFBP-
3 expression in ovarian cancer cell lines
To have a better understanding of the molecular regula-
tion of IGFBP-3, we included two established OEC sub-
lines OVTW59-P0 and P4 for further study. As reported
previously, P4 was more invasive and metastatic than P0;
and P4 expressed very low IGFBP-3 compared to P0 [5].
Using MSP, we detected both 129 bp methylated and 158
unmethylated bands in P0 indicating that P0 was partially
methylated at the IGFBP-3  promoter sites. P4 showed
only a 129 bp band indicating a complete methylation of
the  IGFBP-3  promoter (Figure 3a). 5-aza-deoxycytidine
(5-aza-dC) treatment restored IGFBP-3 expression in P4.
The amount of 5-aza-dC used for treatment directly corre-
lated with IGFBP-3 mRNA and protein expressions (Fig-
ure 3b).
Transcriptional regulation of p53 on IGFBP-3 promoter
Both P0 and P4 expressed similar levels of wild type (wt)
p53 by direct sequencing after amplifying exons 5, 6, 7,
and 8 of p53 gene, and Western blot analysis (data not
shown). To test the transcriptional regulation of IGFBP-3
by p53, the -253 ~+61 portion of the promoter and first
exon of IGFBP-3 were transfected into P0 and P4. After
treatment with a known p53 inhibitor, pifithrin-α, the
luciferase activity representing IGFBP-3 expression was
completely abolished in these two sublines (Figure 3c).
This result indicates that promoter sites between -253
~+61 are essential for transcriptional regulation by p53 on
IGFBP-3 expression
Identification of methylation hotspots at the p53 
consensusbinding sequence in IGFBP-3 promoter
Bisulfite-PCR and sequencing (BSP) was performed in P0
and P4, focusing on the -330 to +140 sites of IGFBP-3 that
included the reported 11 p53 consensus binding sites
[22]. We identified four CpG sites that were frequently
methylated in these two sublines, distributed at the -210,
-206, -183 and -179 loci of IGFBP-3 promoter (Figure 4a).
Kaplan Meier survival estimate of progression-free survival  (PFS) and overall survival (OS) for OEC patients classified by  (a) IGFBP-3 expression, (b) IGFBP-3 promoter methylation  status and (c) p53 expression. (d) Survival estimate for  patients with normal p53, classified according to IGFBP-3  expressions and IGFBP-3 promoter methylation status Figure 2
Kaplan Meier survival estimate of progression-free 
survival (PFS) and overall survival (OS) for OEC 
patients classified by (a) IGFBP-3 expression, (b) 
IGFBP-3 promoter methylation status and (c) p53 
expression. (d) Survival estimate for patients with 
normal p53, classified according to IGFBP-3 expres-
sions and IGFBP-3 promoter methylation status. --- 
indicates patients with high IGFBP-3 and IGFBP-3 promoter 
methylation ≤ 3%; --- indicates patients with unparallel 
IGFBP-3 and IGFBP-3 promoter methylation, i.e. either high 
IGFBP-3 and IGFBP-3 promoter methylation >; 3% or low 
IGFBP-3 and IGFBP-3 promoter methylation ≤ 3%; --·-indi-
cates patients with low IGFBP-3 and IGFBP-3 promoter meth-
ylation > 3%. Logrank test was used to compare survival 
distributions.Molecular Cancer 2009, 8:120 http://www.molecular-cancer.com/content/8/1/120
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Aberrant promoter methylation and transcriptional regulation of p53 at IGFBP-3 Figure 3
Aberrant promoter methylation and transcriptional regulation of p53 at IGFBP-3. (a) MSP shows IGFBP-3 promoter 
methylation in OEC cell lines. Upper panel: schematic diagram showing CpG islands in the IGFBP-3 promoter and the location 
of primers used (M, methylated; U, unmethylated). Arabic numbers indicate the location of nucleotides relative to the tran-
scription start site (TSS) (+1). Vertical lines represent the position of the CpG dinucleotides. Lower panel: MSP in P0 and P4 
sublines. U indicates unmethylated (158 bp) and M indicates methylated (129 bp) PCR products. The SssI treated A549 (lanes 1 
and 2) and H1299 (lanes 4 and 5) were used as methylated controls, A549 as unmethylated control (lanes 6 and 7), and 
Genomic DNA without bisulfite conversion as negative control (lanes 12 and 13). (b) Real-time PCR analysis of IGFBP-3 
mRNA showing restoration of IGFBP-3 expression in P4. P0 and P4 cell lines were treated with 0, 0.1, 0.5 or 2 μM of 5-aza-dC 
for 8 days. Culture media was changed to serum free media for 24 hours before IGFBP-3 analysis. Lower panel shows Western 
blotting corresponding to IGFBP-3 expressions in P0 and P4 culture media after 5-aza-dC treatment. Similar amount of culture 
media from equal number of cells were loaded in each lane. (c) Luciferase activity after transfection with wild type IGFBP-3 
promoter (-253 ~+61)-pGL3 luciferase reporter construct (pGL3-wt IGFBP-3). Luciferase activity was normalized against 
renilla activity. Transfection with pGL3-basic vector (pGL3) was used as negative control. Transfections were carried out in 
triplicate and were done in three independent experiments.Molecular Cancer 2009, 8:120 http://www.molecular-cancer.com/content/8/1/120
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P4 showed a higher frequency of methylation at these loci
compared to P0 (60.7% versus 25.0%) (Figure 4b).
Since p53 binding at these sequences has been reported to
be diminished by methylation [16], we established a
series of site-directed mutation constructs to test the
importance of these four loci on the transcriptional regu-
lation by p53 of IGFBP-3 (Figure 4c). In addition to using
P0 and P4, a human embryonic 293T kidney cell line with
documented wt p53 was also included in analysis. The
transcription activity of IGFBP-3 was significantly reduced
after mutagenesis at these loci and the amount of luci-
ferase activity corresponding to IGFBP-3 expression
decreased as the number of mutated loci increased (Figure
4d). These findings indicate that these four loci are critical
spots for transcriptional regulation by p53 of IGFBP-3. In
addition, methylation at these sites could quantitatively
silence the process of IGFBP-3 induction by p53.
Discussion
We demonstrated previously that IGFBP-3 is an invasion
suppressor in OEC [5]. In this study, we evaluated the
molecular mechanism of IGFBP-3 regulation in cancer
cells and found that methylation at the CpG sites of the
IGFBP-3  promoter was significantly correlated with
IGFBP-3 silencing in OEC tumors. Clinically, patients
with lower IGFBP-3 expression and higher IGFBP-3 pro-
moter methylation have significantly lower PFS and OS.
This association was strongest in cases with normal p53
expression. In an in vitro study using OEC cell line
OVTW59, we identified a quantitative correlation
between IGFBP-3 suppression and methylation in the first
200 base pairs surrounding the transcription start site of
IGFBP-3. Our data suggest that IGFBP-3 silencing through
aberrant hypermethylation at its promoter is a major reg-
ulatory pathway for OEC tumorigenesis.
Methylation specific PCR (MSP) has been widely used to
study promoter methylation in clinical specimens. By
MSP, aberrant methylation at the IGFBP-3 promoter was
found in 44% of epithelial ovarian cancer and in 28.6%
(12/42) of OEC subtype [7,12]. However, IGFBP-3 silenc-
ing has been reported unrelated to IGFBP-3  promoter
methylation [7,12]. A significant association between
IGFBP-3 promoter methylation and disease progression
has been reported, but only in early-stage ovarian cancer
[12]. It was concluded that methylation at IGFBP-3 pro-
moter is a common tumorigenesis process in the early
steps of ovarian cancer progression [12]. By setting the cal-
culated percentage of IGFBP-3 methylation at 3% as a cut-
off point for qMSP analysis, we found methylation at the
IGFBP-3 promoter significantly correlated with IGFBP-3
silencing in OEC. Furthermore, we found patients with
lower IGFBP-3 expression and higher IGFBP-3 promoter
methylation to be significantly associated with poor out-
comes. A possible reason is that we have used a more sen-
sitive method, qMSP, to study these epigenetic events. In
addition, we have focused our study on the OEC subtype
of ovarian cancer. It has been observed that promoter
methylation of specific genes in cancer occur frequently in
a tumor-type and cell-type specific manner [23]. Our
results demonstrate that the clinical significance of aber-
rant IGFBP-3 promoter methylation is more commonly
observed in the OEC subtype of ovarian cancer.
Ten cases in our study showed unparallel results between
IGFBP-3 expression and IGFBP-3 promoter methylation,
i.e. either high IGFBP-3 and IGFBP-3 promoter methyla-
tion > 3% or low IGFBP-3 and IGFBP-3 promoter methyl-
ation  ≤ 3%. Though threshold of > 3% as
hypermethylation was selected based on ROC curve anal-
ysis that showed 0.86 sensitivity and 0.73 specificity of
low IGFBP-3 expression, we found five (50%) of these
unparallel cases were at the third quartile of methylation,
i.e. high IGFBP-3 expression and promoter methylation
levels between 3% and 6.36% (Table 2). This could be due
to inadequate sensitivity and specificity of qMSP assay.
Alternatively, the unparallel result could be explained by
multiple mechanisms of IGFBP-3 regulation. IGFBP-3
could also interact with several other growth-inhibitory
agents to mediate wide varieties of growth suppression
signal in the absence of IGF [24,25]. In addition, other
CpG methylation sites in the IGFBP-3 promoter that were
not studied might also contribute to IGFBP-3 silencing
We further explored the association between p53 and
IGFBP-3  promoter methylation and the mechanism of
p53 regulation on IGFBP-3. Thirty-five percent of these
cases showed p53 overexpression that was correlated with
higher tumor grade at marginal significance. However,
overexpression of p53 was not correlated with IGFBP-3
expression or IGFBP-3 promoter methylation and it did
not correlate with OEC patient survival. This suggested
that p53 is not important in the progression of OEC, and
that IGFBP-3 silencing through promoter methylation is a
mechanism different from p53 overexpression. Since OEC
is similar in histological pattern to the endometrioid (EC)
subtype of endometrial cancer, we reviewed the molecular
characteristics of different subtypes of endometrial cancer.
In endometrial cancer, p53 alteration was specifically
reported to be present in the non-endometrioid (non-EC)
serous subtype, which has been classified as a type 2
endometrial cancer. The EC subtype of endometrial can-
cer is classified as type 1 endometrial cancer [26]. Accord-
ingly, Kurman et al. proposed an epithelial ovarian cancer
model composed of type 1 and type 2 tumors based on:
the histological patterns, molecular features, and the proc-
ess of tumor progression. Type 1 tumors are slow growing,
genetically stable, and are characterized by mutations in
KRAS, BRAF, PTEN, and beta-catenin. Type 2 tumors are
highly aggressive, rapidly growing, genetically instable,
and are characterized by mutation of TP53 [20]. Based onMolecular Cancer 2009, 8:120 http://www.molecular-cancer.com/content/8/1/120
Page 8 of 12
(page number not for citation purposes)
Identification of methylation sites at p53 binding sequence of IGFBP-3 promoter Figure 4
Identification of methylation sites at p53 binding sequence of IGFBP-3 promoter. (a) BSP in P0 and P4. Forty CpG 
sites were shown and each circle represents a CpG dinucleotide. Open circle represents non-methylated CpG dinucleotude 
and black circle represents methylated CpG dinucleotide. The enclosed boxes represent CpG dinucleotide located in the p53 
consensus binding site. Seven clones were sequenced in each cell line. (b) The methylation frequency in P0 and P4 from -210 to 
-179 regions of IGFBP-3 promoter. (c) Schematic diagram of designed constructs for site-directed mutagenesis assay. The wild 
type construct contains IGFBP-3 promoter region from --253 ~+61. The mutant sequences carry the same region but with 
point mutations: (-210, -206) represent as Mut A constructs, and (-183, -179) represent as Mut B constructs. Mut A+B con-
struct contains all four nucleotide mutation. (d) Luciferase activities of 293T and P4 transfected with wild/mutant types of 
IGFBP-3 promoter constructs. Luciferase activity was normalized against renilla activity. Transfection with pGL3-basic vector 
(pGL3) was used as negative control. Transfections were carried out in triplicate and were done in at least three independent 
experiments.Molecular Cancer 2009, 8:120 http://www.molecular-cancer.com/content/8/1/120
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this model, the OEC subtype is classified as a type 1 tumor
and serous subtype, with characteristic TP53 mutations, is
classified as a type 2 tumor [20]. In our study, we con-
firmed that p53 alteration is not a characteristic of OEC.
Instead, low IGFBP-3 and high IGFBP-3 promoter methyl-
ation are major prognostic factors for OEC. By survival
analysis, patient survival is lowest in cases with low
IGFBP-3, high IGFBP-3 promoter methylation, and nor-
mal p53. These suggest OEC is a distinct subtype of ovar-
ian cancer that IGFBP-3 silencing through IGFBP-3
promoter methylation could play an important role in
cancer development and progression. We found p53 alter-
ation is not important for the tumorigenesis of OEC, but
IGFBP-3 silencing through IGFBP-3  promoter methyla-
tion might subsequently interrupt the communication
network between p53 and the IGF axis, and hence lead to
cancer progression of OEC.
Of the eleven p53 binding sites in IGFBP-3 gene that has
been identified [22], Hanafusa et al. observed that at least
four sites between -210 to -150 are essential for p53
induced expression of IGFBP-3 in human hepatocarci-
noma cell line HepG2. They also found that hypermethyl-
ation of these sequences could selectively suppress p53
induced IGFBP-3 expression [16]. Using our OEC cell
line, we identified four sites in the IGFBP-3 promoter at
the -210, -206, -183, and -179 loci, as methylation hot
spots. Functional analyses have been performed to study
the influence of methylation at these sites on the p53 reg-
ulation of IGFBP-3. Hanafusa et al. showed diminished
p53 binding and IGFBP-3 repression associated with
hypermethylation of these sequences by luciferase assay
after co-transfection of p53 and mutant IGFBP-3 pro-
moter constructs, and by electrophoresis mobility shift
assay [16]. In our study, we used pifithrin-α to inhibit p53
and found a subsequent decrease in IGFBP-3 expression
in OVTW59-P4 and 293T cell lines, both of which contain
wt p53. These functional analyses support the observation
that p53 can up-regulate IGFBP-3 expression [27], and
methylation at these sites suppress the p53 activation of
IGFBP-3.
Furthermore, our results show a quantitative association
between methylation at the IGFBP-3  promoter and
IGFBP-3 expression. The amount of methylation at these
hot spots were positively related to IGFBP-3 suppressions
in the P0 and P4 sublines. Using site-directed mutagene-
sis, we demonstrated a linear correlation between IGFBP-
3 suppression and the amount of methylation at these
loci. Our in vitro data support our clinical qMSP finding
that IGFBP-3 expression was correlated to IGFBP-3 pro-
moter methylation in OEC tumors.
Our observation that normal p53 is a required factor
along with lower IGFBP-3 and higher IGFBP-3 promoter
methylation for a significant survival result also suggests
that wt p53 is an important molecular characteristic of
OEC subtype. Recently, Kawasaki et al. reported an inverse
association between IGFBP-3 promoter methylation and
microsatellite instability in patients with methylator phe-
notype colorectal cancers, particularly under the condi-
tion of wt p53 [28]. We postulate that the biological
environment of IGFBP-3 promoter methylation is strictly
regulated, such that wt p53 and un-methylated IGFBP-3
promoter region are necessary factors to maintain a home-
ostatic condition.
Progression of tumorigenesis involves multiple steps of
genetic alteration. From OEC clinical specimens and cell
lines, our data indicates that aberrant methylation at p53
consensus sequence binding region of IGFBP-3 promoter
could contribute to low IGFBP-3 expression and subse-
quently to a poor patient survival outcome. Normal p53
plays an important role in this regulation. In conclusion,
our studies show clinical evidence on methylation-
dependent epigenetic silencing of IGFBP-3 expression reg-
ulated by p53. This regulatory pathway represents an
important mechanism for loss of IGFBP-3 expression dur-
ing OEC tumorigenesis and/or progression to metastasis.
Methods
Chemical reagents
General laboratory reagents were purchased from Sigma-
Aldrich (St. Louis, MO, USA) and cell culture reagents
from Gibco/BRL (Grand Island, NY, USA), unless other-
wise specified. 5-aza-dC was obtained from Sigma-Aldrich
and pifithrin-α from Calbiochem (Gibbstown, NJ, USA).
Tumor specimen and cell lines
Sixty cases of OEC specimens were collected from the
archive of Department of Pathology, National Taiwan
University (NTU) Hospital from May, 1994 to September
2006. These patients received surgeries and chemothera-
pies according to our previous report [29]. Informed con-
sents were obtained for each patient before receiving
operations. OEC cell lines OVTW59-P0 and P4 were
established in our laboratory previously [5]. Cell lines
A549, H1299 and 293T were obtained from Taiwan
National Health Research Institute cell bank. All cell lines
were maintained in DMEM solution with 5% FCS.
Immunohistochemical staining
Staining was performed in 4 μm paraffin sections as
described previously [29]. In brief, sections were dewaxed,
rehydrated, heated by microwave and then blocked with
1% H2O2 and normal horse serum. Antibodies against
IGFBP-3 (Sigma-Aldrich) and p53 (clone DO-7; DAKO,
Glostrup, Denmark), as the primary antibodies, were
incubated, followed by biotinylated secondary antibod-
ies, avidin-biotin-peroxidase complex and peroxidaseMolecular Cancer 2009, 8:120 http://www.molecular-cancer.com/content/8/1/120
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substrate were then added for microscopic observation.
Interpretations of immunostaining were performed inde-
pendently by two authors (PLT and CTL). Immunostain-
ing of IGFBP-3 was defined as low or high when less or
more, respectively, than 25% of tumor cells exhibited
strong staining of cytoplasm. Immunostaining of p53 was
defined as normal or overexpressed when less or more,
respectively, than 25% of tumor cells exhibited strong
nuclear staining.
Bisulfite modification
Tumor parts from 10 μm paraffin sections were dissected
under a stereomicroscope for DNA isolation. An estima-
tion of greater than 80% purity of tumor cells was
obtained in each case. Genomic DNA was extracted using
QlAamp DNA kit (Qiagene, Valencia, CA, USA) and sub-
jected to EpiTect Bisulfite kit (Qiagene) according to the
manufacture's protocol. In brief, 2 μg of genomic DNA
was subjected to a denature/incubation repeat cycle in
sodium bisulfite solution.
Quantitative real time methylation specific PCR (qMSP)
Bisulphite converted DNA was subjected to real time
qMSP using ABI StepOne real time PCR system (Applied
Biosystems, Foster City, CA) as previously described [30]
with slight modification. In Brief, each reaction contained
12.5 μL of 2 × SYBR green PCR mix (Toyobo, Japan), 160
nM of each primer and 4 μl of bisulphite modified DNA
in a total volume of 25 μl at 95°C for 10 min, 40 cycles of
95°C for 15 sec, 67°C for 30 sec, and 72°C for 30 sec.
Primers targeting the IGFBP3  promoter region were
shown in Table 4. β-actin (ACTB) was used to normalize
for input DNA. A region of ACTB devoid of any CpG dinu-
cleotide was amplified using the following primer
sequences: forward, 5' TGGTGATGGAGGAGGTTTAG-
TAAGT and reverse, 5' AACCAATAAAACCTACTCCTC-
CCTTAA. The amount of methylated IGFBP3 and ACTB
were determined by the threshold cycle number (Ct) for
each sample against a standard curve generated by SssI-
treated DNA (Millipore, Billerica, MA)-MSP cloned frag-
ment. The sequence of the fragment was confirmed by
sequencing reaction. The performance of the standard
curve was shown in additional file 1, Figure S3. The per-
centage of IGFBP3 methylation was calculated as the
IGFBP3:ACTB ratio of a sample divided by the same ratio
of SssI-treated sperm DNA (Millipore, Billerica, MA) and
multiplying by 100
Methylation-specific PCR (MSP)
Primers for methylated and unmethylaled region of
IGFBP-3 promoter, as previously reported [31], are listed
in Table 3. The schematic diagram showing the locations
of primers used are shown in Figure 1a. Twenty μL of reac-
tion volume containing one-twentieth of the modified
DNA, 4 deoxynucleoside triphosphates, PCR primers (-
MSP) and HotStar TaqDNA MasterMix (Qiagen, Valencia,
CA) were set for first PCR. The PCR product was then used
as DNA template for a second methylated (-M) or
unmethylated (-U) IGFBP-3 PCR reaction. Results were
resolved by electrophoresis using 2% agarose gels. Cell
line A549 treated with SssI was used as a positive methyl-
ated control.
Bisulfite-PCR and sequencing (BSP)
The -372 ~+140 bp from the first exon of IGFBP-3 pro-
moter region was amplified from one-twentieth of the
modified DNA by PCR using HotStarTaq DNA Master Mix
Kit (Qiagene, Valencia, CA). The primer sequences and
PCR conditions are shown in Table 4. The pGEM-T Easy
Vector (Promega Corp., Madison, WI, USA) was used for
TA cloning and high-efficiency competent cells DH5α
(Yeastern, Taipei, Taiwan) was used for transformation.
Colonies were selected and rechecked by electrophoresis.
The recovered plasmids were sequenced at the Sequencing
Core Facility of the NTU College of Medicine. Cytosines in
CpG dinucleotides that remained unconverted after
bisulfite treatment were considered as methylated.
Western blotting
Twenty-fold concentrated conditioned media, collected
from cells cultured in FCS-free DMEM media for 24 hours,
were subjected to 8% SDS-PAGE (Millipore, Bedford, MA,
USA) and then transferred to membranes (Schleicher &
Schuell, Germany) using MilliBlot-SDS semi-dry electrob-
lotting system (Millipore). After blocking, the membrane
were probed with antibodies against IGFBP-3 (Research
Reagents, Texas, USA). Reactions were amplified by bioti-
nylated second antibody, followed by streptavidin-HRP.
Results were exposed using ECL system.
cDNA preparation and quantitative real time reverse-
transcriptase PCR (QRT-PCR)
Total RNA was extracted using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) and cDNA was prepared using Super-
Script III First-strand Synthesis of the Oligo (dT) primer sys-
tem (Invitrogen). The cDNA samples were subjected to QRT-
PCR as described previously [5] using 7700 Sequence Detec-
tor (Applied Biosystems, Foster City, CA, USA) and SYBR
green Master Mix Kit (Alppied Biosystems). Primer
sequences for IGFBP-3 were forward: 5' TGTGGCCATGACT-
GAGGAAA, reverse: 5' TGCCAGACCTTCTTGGGTTT; and
GAPDH were forward: 5' TGGTATCGTGGAAGGACTCA,
reverse: 5' AGTGGGTGTCGCTGTTGAAG. Each target gene
was normalized to GAPDH mRNA expression for compari-
son.
Construction of wild and mutant expression vectors
The promoter region of IGFBP-3 (from -253 ~+61) and
the site-directed mutagenesis constructs at 4 different
mutant sites (C to A at -210, -206, -183 and -179) were
generated by PCR amplification with primers and PCR
conditions as shown in Table 4. Wild type pGL3-IGFBP-3Molecular Cancer 2009, 8:120 http://www.molecular-cancer.com/content/8/1/120
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and the mutant constructs were generated by subcloning
of the PCR fragments to pGL3-Basic plasmid (Promega
Corp.). The mutant constructs were named as Mut A
(mutation at -210 and -206), Mut B (mutation at -183 and
-179) and Mut A+B (mutant at all of the four sites), respec-
tively, as shown in Figure 3c. All constructs were con-
firmed by DNA sequencing.
Transient transfection and luciferase assays
Cells were transiently transfected using Arrest-In transfec-
tion reagents (Open Biosystems, Huntsville, USA). Cells
at a density of 1 × 105/well were seeded in 6-well plate.
Transfection was performed using 2 μg of plasmid DNA in
serum free medium for 6 hours. Cells were then incubated
in serum containing medium for another 48 hours. After
washing twice with PBS, cells were collected for luciferase
assays (Promega Corp.) using a dual luciferase reporter
assay system according to the manufacture's instructions.
The relative luciferase activity was normalized against
renilla activity by co-transfection with 1 μg of pRL-TK
(Promega Corp.).
Statistical analysis
The cutoff value of IGFBP-3 methylation as a threshold of
hypermethylation was identified using ROC curve and
AUC. The expressions of IGFBP-3 and p53, and IGFBP-3
methylation status were compared among patients with
different clinical and pathologic features using t test and
χ2 test. Associations among IGFBP-3 expression, p53 over-
expression and IGFBP-3 promoter methylation with pro-
gression-free survival (PFS) and overall survival (OS) rates
were assessed by Cox-regression analysis. Kaplan-Meier
analysis with logrank test was used to estimate survival
probabilities and to compare survival distributions cate-
gorized by IGFBP-3 expression, IGFBP-3 promoter meth-
ylation and p53 overexpression. Statistical analysis was
carried out using Statistical Analysis System (SAS) version
8.0 (SAS Institute, Cary, NC). Probability values less than
0.05 were regarded as significant.
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Table 4: Primer sequences for IGFBP-3 analysis.
Annealing °C (Cycle)  Size (bp) 
Quantitative real time methylation-specific PCR
IGFBP3 F: 5'- AGGTGATTCGGGTTTCGGGC -3'
R: 5'- GACCCGAACGCGCCG -3'
60 (40) 223
Methylation-specific PCR
IGFBP3_MSP F: 5'-TCGGGTATATTTTGGTTTTTGTAG-3'
R: 5'-AAACATATAAAATCCAAACAAAAA-3'
55 (30) 351
IGFBP3_M
(methythlated)
F: 5'CGAAGTACGGGTTTCGTAGTCG-3'
R: 5'-CGAC CCGAACGCGCCGACC-3'
66 (40) 129
IGFBP3_U
(unmethylated)
F: 5'-TTGGTTGTTTAGGGTGAAGTATGGGT-3'
R: 5'-CACCCAACCACAATACTCACATC-3'
64 (40) 158
Bisulphate-PCR
IGFBP3 F: 5'-TTTGAGAGTGGAAGGGGTAAGGG-3'
R: 5'-CCCACTACATAACACCTACAACC-3'
53 (40) 512
Mutagenesis
Wild type IGFBP3 F: 5'-GGGCACACCTTGGTTCTTGTAG-3'
R: 5'-TTCCTGCCTGGATTCCACAGCT-3'
52 (40) 316
Mutant (M12) IGFBP3 F: 5'-ACAAGGTGACCCGGGCTCAGGGAGTGAGCACGAGGAGCAGGT-3'
R: 5'-ACCTGCTCCTCGTGCTCACTCCCTGAGCCCGGGTCACCTTGT-3'
55 (12)
Mutant (M34) IGFBP3 F: 5'-GCACGAGGAGACGGTGCCAGGGAGAGTCTCAAGCTCCACGCC-3'
R: 5'-GGCGTGCAGCTTGAGACTCTCCCTGGCACCTGCTCCTCGTGC-3'
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